Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHOK PATEL

NPI
1093809576
CMS profile
276954
Location
TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$14,560.76

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Otsuka America Pharmaceutical, Inc. $13,844.54 20
ABBVIE INC. $291.15 23
ACADIA Pharmaceuticals Inc $244.82 2
Takeda Pharmaceuticals U.S.A., Inc. $88.39 6
Eisai Inc. $56.75 2
Lilly USA, LLC $19.84 1
UCB, Inc. $15.27 1

Page 1 of 2; records 1–50 of 55 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHOK PATEL

NPI 1093809576 · CMS profile ID 276954

TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 55 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093809576?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 55 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093809576?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 55 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093809576?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 55 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093809576?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $14,560.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $14.0112/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083419 CMS
Otsuka America Pharmaceutical, Inc. $4,824.0012/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673271 CMS
Otsuka America Pharmaceutical, Inc. $41.1812/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673283 CMS
Otsuka America Pharmaceutical, Inc. $81.6112/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673295 CMS
ABBVIE INC. $25.5612/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083417 CMS
ABBVIE INC. $16.1212/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083415 CMS
ABBVIE INC. $17.7411/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083413 CMS
Otsuka America Pharmaceutical, Inc. $1,472.2011/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673259 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.8911/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055530715 CMS
ABBVIE INC. $16.5211/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083411 CMS
ABBVIE INC. $8.6611/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083409 CMS
ABBVIE INC. $8.0911/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083407 CMS
Eisai Inc. $40.0010/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045413159 CMS
Otsuka America Pharmaceutical, Inc. $124.9710/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673247 CMS
Otsuka America Pharmaceutical, Inc. $30.2010/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673235 CMS
Otsuka America Pharmaceutical, Inc. $210.9010/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673165 CMS
Otsuka America Pharmaceutical, Inc. $823.4010/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673175 CMS
Otsuka America Pharmaceutical, Inc. $348.2910/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673189 CMS
Otsuka America Pharmaceutical, Inc. $27.7710/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673199 CMS
Otsuka America Pharmaceutical, Inc. $39.6810/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673211 CMS
Otsuka America Pharmaceutical, Inc. $31.0310/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673225 CMS
ABBVIE INC. $11.4510/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083405 CMS
ABBVIE INC. $9.0010/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083403 CMS
ABBVIE INC. $6.8310/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083399 CMS
ABBVIE INC. $12.0310/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083401 CMS
ABBVIE INC. $14.8209/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083397 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.9509/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055530709 CMS
ABBVIE INC. $11.3009/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083395 CMS
Otsuka America Pharmaceutical, Inc. $2,106.0009/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673153 CMS
Otsuka America Pharmaceutical, Inc. $18.6409/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673141 CMS
ABBVIE INC. $12.0309/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083393 CMS
ABBVIE INC. $17.8908/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083391 CMS
Otsuka America Pharmaceutical, Inc. $2,106.0008/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673129 CMS
ABBVIE INC. $14.8508/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083389 CMS
Otsuka America Pharmaceutical, Inc. $121.5508/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.8408/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055530705 CMS
ABBVIE INC. $6.4308/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083383 CMS
ABBVIE INC. $1.0008/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083385 CMS
ABBVIE INC. $16.3608/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083387 CMS
Eisai Inc. $16.7508/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045413153 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.0408/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055530699 CMS
Otsuka America Pharmaceutical, Inc. $351.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673107 CMS
ABBVIE INC. $7.3707/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083381 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.2007/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055530691 CMS
ABBVIE INC. $15.7006/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083379 CMS
Otsuka America Pharmaceutical, Inc. $1,053.0006/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673095 CMS
ACADIA Pharmaceuticals Inc $122.4105/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053155873 CMS
ACADIA Pharmaceuticals Inc $122.4105/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053155877 CMS
Otsuka America Pharmaceutical, Inc. $18.1305/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673083 CMS
Otsuka America Pharmaceutical, Inc. $14.9903/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014673073 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.42 66
PY2020 $2,969.84 33
PY2021 $7,553.27 35
PY2022 $6,054.38 18
PY2023 $14,560.76 55
PY2024 $22,723.92 31
PY2025 $6,910.62 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,752.51 11
PY2025 Principal investigator $1,229,009.00 130
PY2024 Principal investigator $3,194,861.98 28
PY2023 Recipient $355.00 1
PY2023 Principal investigator $1,914,939.19 59
PY2022 Recipient $1,248.00 4
PY2022 Principal investigator $1,105,512.02 75
PY2021 Recipient $13,374.00 3
PY2021 Principal investigator $1,695,784.21 81
PY2020 Recipient $6,288.97 21
PY2020 Principal investigator $1,118,610.73 104
PY2019 Recipient $18,854.85 12
PY2019 Principal investigator $1,138,230.38 171

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $473.25 12/31/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH INC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998413523
Principal investigator 1 Eisai Inc. $10,175.40 12/14/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935623
Principal investigator 1 BioXcel Therapeutics, Inc. $116,100.90 11/29/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1057507209
Principal investigator 1 BioXcel Therapeutics, Inc. $155,534.50 11/29/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1057507271
Principal investigator 1 Eisai Inc. $8,626.50 11/22/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935613
Principal investigator 1 BioXcel Therapeutics, Inc. $384,500.00 11/21/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1057507199
Principal investigator 1 ABBVIE INC. $477.00 11/09/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998407681
Principal investigator 1 ABBVIE INC. $7,500.00 11/03/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998405749
Principal investigator 1 BioXcel Therapeutics, Inc. $248,058.90 10/26/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1057507075
Principal investigator 1 BioXcel Therapeutics, Inc. $27,360.00 10/26/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1057507117
Principal investigator 1 Eisai Inc. $11,639.39 10/19/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935601
Principal investigator 1 ABBVIE INC. $400.00 10/17/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998404381
Principal investigator 1 BioXcel Therapeutics, Inc. $281,985.40 10/06/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1057506985
Principal investigator 1 BioXcel Therapeutics, Inc. $1,750.00 10/02/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA No dispute reported 06/30/2026 1057506975
Principal investigator 1 ITI, Inc. $9,290.47 09/29/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042725683
Principal investigator 1 Eisai Inc. $17,462.70 09/26/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935589
Principal investigator 1 ITI, Inc. $105.00 09/22/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042725655
Principal investigator 1 ITI, Inc. $11,724.35 08/25/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042724395
Principal investigator 1 ABBVIE INC. $300.00 08/24/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998396511
Principal investigator 1 Eisai Inc. $7,674.30 08/18/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935579
Principal investigator 1 ITI, Inc. $5,000.00 08/18/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042724231
Principal investigator 1 ABBVIE INC. $3,850.00 08/17/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998395737
Principal investigator 1 ABBVIE INC. $3,000.00 08/16/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998395641
Principal investigator 1 ABBVIE INC. $1,500.00 08/09/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998393499
Principal investigator 1 ITI, Inc. $17,549.42 07/28/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042723033
Principal investigator 1 Eisai Inc. $25,246.80 07/24/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935567
Principal investigator 1 ITI, Inc. $10,019.10 06/30/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042721623
Principal investigator 1 ITI, Inc. $11,425.65 06/30/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042721691
Principal investigator 1 ABBVIE INC. $150.00 05/30/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998384739
Principal investigator 1 ABBVIE INC. $450.00 05/30/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998384741
Principal investigator 1 ABBVIE INC. $5,713.40 05/30/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998384743
Principal investigator 1 ITI, Inc. $10,275.96 05/26/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042720083
Principal investigator 1 ITI, Inc. $8,473.87 05/26/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042720155
Principal investigator 1 Eisai Inc. $9,723.60 05/19/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935555
Principal investigator 1 ITI, Inc. $15,000.00 05/19/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042719691
Principal investigator 1 ITI, Inc. $10,391.50 04/28/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042718637
Principal investigator 1 ABBVIE INC. $27,562.98 04/05/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998376635
Principal investigator 1 Eisai Inc. $33,966.80 04/05/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935533
Principal investigator 1 Eisai Inc. $23,013.00 04/05/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935543
Principal investigator 1 ITI, Inc. $15,897.62 03/24/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042717641
Principal investigator 1 ITI, Inc. $15,448.42 03/24/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042717673
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $10,299.62 03/22/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC-34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1014041805
Principal investigator 1 Eli Lilly and Company $500.00 03/21/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 2 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 1038072995
Principal investigator 1 ABBVIE INC. $20,220.80 03/09/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998373451
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $4,025.00 03/09/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A 12-WEEK, MULTICENTER, ACTIVE-TREATMENT EXTENSION TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE No dispute reported 06/30/2026 1014041613
Principal investigator 1 ITI, Inc. $13,639.88 02/24/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042716637
Principal investigator 1 ITI, Inc. $15,870.94 02/24/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042716655
Principal investigator 1 Eli Lilly and Company $3,049.58 02/23/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038091282
Principal investigator 1 Eisai Inc. $4,060.41 02/20/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935521
Recipient Eli Lilly and Company $355.00 01/31/2023 Covered Recipient Physician A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038047533
Principal investigator 1 ITI, Inc. $12,068.34 01/27/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042715461
Principal investigator 1 ITI, Inc. $24,239.42 01/27/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1042715489
Principal investigator 1 ABBVIE INC. $6,000.00 01/26/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 998367313
Principal investigator 1 ABBVIE INC. $4,000.00 01/26/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 998367315
Principal investigator 1 ABBVIE INC. $2,000.00 01/26/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 998367317
Principal investigator 1 Eisai Inc. $6,483.60 01/20/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935509
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $19,399.76 01/18/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 1014038015
Principal investigator 1 ABBVIE INC. $26,005.86 01/11/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 998364965
Principal investigator 1 Eli Lilly and Company $176,146.00 01/10/2023 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038071583
Principal investigator 1 Eisai Inc. $12,133.80 01/06/2023 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1039935497